155 related articles for article (PubMed ID: 28830009)
1. Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis.
Tati S; Fisk JC; Abdullah J; Karacosta L; Chrisikos T; Philbin P; Morey S; Ghazal D; Zazala F; Jessee J; Quataert S; Koury S; Moreno D; Eng JY; Glinsky VV; Glinskii OV; Sesay M; Gebhard AW; Birthare K; Olson JR; Rittenhouse-Olson K
Neoplasia; 2017 Sep; 19(9):716-733. PubMed ID: 28830009
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging.
Karacosta LG; Fisk JC; Jessee J; Tati S; Turner B; Ghazal D; Ludwig R; Johnson H; Adams J; Sajjad M; Koury S; Roy R; Olson JR; Rittenhouse-Olson K
Transl Oncol; 2018 Apr; 11(2):450-466. PubMed ID: 29477636
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of the humanized JAA-F11 anti-Thomsen-Friedenreich antibody constructs H2aL2a and H3L3 in human breast and lung cancer xenograft models.
Ghazal D; Zalzala F; Fisk JC; Tati S; Karacosta LG; Morey S; Olson JR; Quataert S; Dy GK; Rittenhouse-Olson K
Oncotarget; 2022 Oct; 13():1155-1164. PubMed ID: 36264086
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies with JAA-F11 anti-Thomsen-Friedenreich monoclonal antibody for human breast cancer.
Ferguson K; Yadav A; Morey S; Abdullah J; Hrysenko G; Eng JY; Sajjad M; Koury S; Rittenhouse-Olson K
Future Oncol; 2014 Feb; 10(3):385-99. PubMed ID: 24559446
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11.
Heimburg J; Yan J; Morey S; Glinskii OV; Huxley VH; Wild L; Klick R; Roy R; Glinsky VV; Rittenhouse-Olson K
Neoplasia; 2006 Nov; 8(11):939-48. PubMed ID: 17132226
[TBL] [Abstract][Full Text] [Related]
6. Jaa-f11: extending the life of mice with breast cancer.
Rittenhouse-Olson K
Expert Opin Biol Ther; 2007 Jul; 7(7):923-8. PubMed ID: 17665983
[TBL] [Abstract][Full Text] [Related]
7. Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy.
Almogren A; Abdullah J; Ghapure K; Ferguson K; Glinsky VV; Rittenhouse-Olson K
Front Biosci (Schol Ed); 2012 Jan; 4(3):840-63. PubMed ID: 22202095
[TBL] [Abstract][Full Text] [Related]
8. Tumor immunolocalization using 124 I-iodine-labeled JAA-F11 antibody to Thomsen-Friedenreich alpha-linked antigen.
Chaturvedi R; Heimburg J; Yan J; Koury S; Sajjad M; Abdel-Nabi HH; Rittenhouse-Olson K
Appl Radiat Isot; 2008 Mar; 66(3):278-87. PubMed ID: 17890096
[TBL] [Abstract][Full Text] [Related]
9. Development, characterization, and immunotherapeutic use of peptide mimics of the Thomsen-Friedenreich carbohydrate antigen.
Heimburg-Molinaro J; Almogren A; Morey S; Glinskii OV; Roy R; Wilding GE; Cheng RP; Glinsky VV; Rittenhouse-Olson K
Neoplasia; 2009 Aug; 11(8):780-92. PubMed ID: 19649208
[TBL] [Abstract][Full Text] [Related]
10. Corrigendum to "Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and In Vitro Efficacy Analysis" [Neoplasia 19.9 (2017) 716-733].
Tati S; Fisk JC; Abdullah J; Karacosta L; Chrisikos T; Philbin P; Morey S; Ghazal D; Zalzala F; Jessee J; Quataert S; Koury S; Moreno D; Eng JY; Glinsky VV; Glinskii OV; Sesay M; Gebhard AW; Birthare K; Olson JR; Rittenhouse-Olson K
Neoplasia; 2018 Jan; 20(1):118. PubMed ID: 29277397
[No Abstract] [Full Text] [Related]
11. Computational screening of the human TF-glycome provides a structural definition for the specificity of anti-tumor antibody JAA-F11.
Tessier MB; Grant OC; Heimburg-Molinaro J; Smith D; Jadey S; Gulick AM; Glushka J; Deutscher SL; Rittenhouse-Olson K; Woods RJ
PLoS One; 2013; 8(1):e54874. PubMed ID: 23365681
[TBL] [Abstract][Full Text] [Related]
12. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
[TBL] [Abstract][Full Text] [Related]
13. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
[TBL] [Abstract][Full Text] [Related]
14. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
15. The Potential Action of Thomsen-Friedenreich Monoclonal Antibody (A78-G/A7) in Thyroid Cancer.
Peng Y; Zhan XX; Cao Y; Zhang HW; Cao WH; Su YJ; Diao C; Sun QM; Cheng RC
Onco Targets Ther; 2020; 13():8677-8689. PubMed ID: 32982276
[TBL] [Abstract][Full Text] [Related]
16. Multivalent scFv display of phagemid repertoires for the selection of carbohydrate-specific antibodies and its application to the Thomsen-Friedenreich antigen.
Ravn P; Danielczyk A; Jensen KB; Kristensen P; Christensen PA; Larsen M; Karsten U; Goletz S
J Mol Biol; 2004 Oct; 343(4):985-96. PubMed ID: 15476815
[TBL] [Abstract][Full Text] [Related]
17. Mouse monoclonal antibody to a melanoma-carcinoma-associated antigen synthesized by a human melanoma cell line propagated in serum-free medium.
Chee DO; Yonemoto RH; Leong SP; Richards GF; Smith VR; Klotz JL; Goto RM; Gascon RL; Drushella MM
Cancer Res; 1982 Aug; 42(8):3142-7. PubMed ID: 7046918
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers.
Longenecker BM; Willans DJ; MacLean GD; Selvaraj S; Suresh MR; Noujaim AA
J Natl Cancer Inst; 1987 Mar; 78(3):489-96. PubMed ID: 3469463
[TBL] [Abstract][Full Text] [Related]
19. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.
Schindlbeck C; Jeschke U; Schulze S; Karsten U; Janni W; Rack B; Sommer H; Friese K
Histochem Cell Biol; 2005 Jun; 123(6):631-7. PubMed ID: 15889266
[TBL] [Abstract][Full Text] [Related]
20. The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs.
Ravn P; Stahn R; Danielczyk A; Faulstich D; Karsten U; Goletz S
Cancer Immunol Immunother; 2007 Sep; 56(9):1345-57. PubMed ID: 17310382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
